Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?

Company hopes TAF-based combo incorporating integrase inhibitor bictegravir can help it compete with ViiV, but beyond that pipeline holds only early-stage and smaller opportunities in HIV. Analysts call on Gilead to use its cash stockpile to find its next R&D focus.

Economics graph

The HIV drug space has narrowed in recent years, now down largely to two major players – Gilead Sciences Inc., which continues to hold the top spot, and ViiV Healthcare, the GlaxoSmithKline PLC/Pfizer Inc. joint venture founded in 2009.

ViiV has begun to gain ground on Gilead, powered by the strength of recent launches, though Gilead has maintained its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip